seperator

Board of Directors

seperator

 

Thomas W. Chalberg, PhD is a scientist and biotechnology investor and entrepreneur. Dr. Chalberg is a founder and operating executive of multiple life science companies, including SightGlass Vision, iRenix, and Genascence. Previously, Thomas has served in various executive roles at biotechnology companies, including as Chief Operating Officer of Oncorus, Inc.; Founder/CEO of Avalanche Biotechnologies (now ADVM); and a member of the ophthalmology team at Genentech. Thomas has received awards and recognition from the Foundation Fighting Blindness and the World Economic Forum for his contributions to biotechnology. He received his AB in biochemistry from Harvard College, PhD in genetics from Stanford University School of Medicine, and MBA from the Haas School of Business at the University of California, Berkeley.

Justin Duckworth is a Managing Partner of the QureInvest investment Fund and also sits on the Board of HS LifeSciences AG and Transimmune AG. Mr Duckworth has spent the last 20 years working in venture capital within life sciences. Prior to QureInvest he was a Partner in the team at Nomura Phase4 Ventures and also worked at HBM Partners in Zurich and Dresdner Kleinwort Capital in London. He has a biochemistry degree from Oxford University and is a member of the Institute for Chartered Accountants.

Karsten Henco started his industrial career in the 1980s when he was involved in the establishment of the molecular biology and recombinant DNA technology facilities of BASF AG in Ludwigshafen, Germany. He is co-founder or co-founding investor of fourteen biotech companies in Germany, USA, Canada and Austria, such as Qiagen NV, Evotec AG, NewLab AG, Coley Pharmaceuticals Inc, U3 Pharma AG, Neurimmune Therapeutics AG, HS LifeSciences and QureInvest. He acted as CEO, Chairman or Board member in several of these companies and others, too. Karsten Henco serves as an advisor for HighTech Gründerfonds of the German government. He studied biochemistry in the University of Hannover and at the University of Darmstadt where he was awarded his PhD. Karsten completed his post-doctoral training at Prof. Charles Weissmann’s lab in the University of Zürich, Switzerland.

Gerd Maass began his career in the 1990s, working as a scientist at the Institute for Molecular Pathology Vienna before being appointed the Department Head of Gene Therapy at MediGene AG in Munich. He joined Roche in 1997 as International Program Manager and held a number of senior positions over his 20 years with the company, including most recently Member of the Roche CEO Office and European Head of Foundation Medicine. He studied microbiology and molecular biology at the University of Heidelberg and completed his Ph.D. on AIDS research at Tübingen University and Boehringer Mannheim.

Mr. Justin Duckworth

Managing Partner HS Life Sciences

Dr. Karsten Henco

Managing Partner and Co-Founder HS Life Sciences

Dr. Gerd Maass

Head of Molecular Information Region Europe Roche Pharmaceuticals

Dr. Thomas Chalberg

CEO/CSO SightGlass Vision Inc.

Learn more about our investors.

GO TO INVESTORS